Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Researchers have discovered a new approach to prostate cancer treatment by combining immunotherapy with PIM1 kinase ...

Researchers at University of Arizona Cancer Center used a double-pronged approach to reduce tumor growth in tissue samples of ...

A new study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

An experimental treatment for an aggressive and lethal brain cancer has been published in Nature Medicine, paving the way for ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherapy through ...

Joe Leach, MD, discusses some of the latest developments in incorporating immunotherapy into small cell lung cancer treatment regimens.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...